Rebecca C. Hull
Dundee, SCT, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
A framework for translational research in interstitial lung disease (ILD) using bronchoalveolar lavage (BAL).
Journal: Expert review of clinical immunology
Published: May 15, 2026
The frequent exacerbator phenotype in bronchiectasis revisited: Data from EMBARC registry.
Journal: American journal of respiratory and critical care medicine
Published: April 01, 2026
Taking a wider view: The Lancet Respiratory Medicine Commission on bronchiectasis.
Journal: The Lancet. Respiratory medicine
Published: January 11, 2026
Comorbid diabetes disease severity and microbial changes in patients with bronchiectasis: a combined analysis of data from the EMBARC, EMBARC-India, Australian, and BE-China registries.
Journal: The Lancet. Respiratory medicine
Published: December 23, 2025
Author Correction: Hypoxia induces histone clipping and H3K4me3 loss in neutrophil progenitors resulting in long-term impairment of neutrophil immunity.
Journal: Nature immunology
Published: December 01, 2025
Rapid molecular detection of respiratory pathogens in patients with bronchiectasis.
Journal: ERJ open research
Published: November 06, 2025
Assessment of a bacterial quantification assay to detect and monitor Pseudomonas aeruginosa infection in patients with bronchiectasis.
Journal: ERJ open research
Published: October 08, 2025
Reply to Tang and Sun, and to Deng and Liu.
Journal: American journal of respiratory and critical care medicine
Published: September 15, 2025
Aspergillus fumigatus Sensitization Is Associated With High-Risk Bronchiectasis.
Journal: Chest
Published: August 25, 2025
Aspergillus fumigatus Sensitization Is Associated With High-Risk Bronchiectasis.
Journal: Chest
Published: August 25, 2025
Endotypes of Pseudomonas aeruginosa Infection in Bronchiectasis Are Associated with Inhaled Antibiotic Response: Results from Two Randomized, Double-Blind, Placebo-controlled Phase III Trials (ORBIT 3 and ORBIT 4).
Journal: American journal of respiratory and critical care medicine
Published: July 15, 2025
Design and rationale of the AIR-NET trial: a randomised, open-label, multifactorial, multicentre, adaptive platform trial using a range of repurposed anti-inflammatory treatments to improve outcomes in patients with bronchiectasis within the EMBARC clinical research network.
Journal: ERJ open research
Published: May 02, 2025
Last Updated: 09/26/2026